Product Description
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Colorectal Cancer|Kidney Diseases|Melanoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Small Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03239145 |
NCT03239145 | P1 |
Completed |
Melanoma|Ovarian Cancer|Colorectal Cancer|Small Cell Lung Cancer|Kidney Diseases|Non-Small-Cell Lung Cancer |
2024-12-13 |
12% |
2025-06-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date |